ARTICLE | Company News
NVS's Glivec receives priority status
March 26, 2001 8:00 AM UTC
The FDA assigned priority review status for Glivec to treat chronic myeloid leukemia (CML) in patients refractory to interferon-alpha therapy. Glivec is a small molecule inhibitor of the Bcr-Abl kinas...